article thumbnail

Goodbye 2023, Hello 2024!

Contrarian Sales Techniques

Highlights of the Year 2023 has been a transformative year in the world of sales, marked by significant advancements and innovations. On this blog, we've explored and implemented cutting-edge sales strategies and techniques that have redefined how we approach selling.

Sales 64
article thumbnail

How health plans can leverage competitive intelligence data today to drive impact in 2024

Clarify Health

The strategic use of competitive intelligence data is increasingly becoming a crucial factor for healthcare payers looking to make informed decisions around strategic market expansion and strengthen their market position.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Promising schizophrenia drug faces tough competition

European Pharmaceutical Review

GlobalData’s report showed LY03010 is expected to launch in the US in 2024. If successful, the drug is forecasted to reach sales of $63.5 The post Promising schizophrenia drug faces tough competition appeared first on European Pharmaceutical Review. million in 2031, representing 0.6

article thumbnail

Selling To Distributors: 9 Steps For Success In 2024

Spotio

This sales model has many different advantages. At the end of the day, distributors simplify the sales process for manufacturers. Others use specific methods to ensure more sales. In other words, you need to select sales channels for yourself and/or your sales team. Why Sell To Distributors?

Retail 52
article thumbnail

FDA approves first Stelara biosimilar, Wezlana

European Pharmaceutical Review

Sustainable biosimilar competition in Europe: can it be achieved? We do not expect entry of Stelara biosimilars in the United States during 2024,” Joseph Wolk CFO, Johnson & Johnson, stated during the company’s Q3 earnings call on 18 October. US sales of Stelara totalled $6.4

article thumbnail

Consequences of the First 10 Drugs Selected for Medicare’s Negotiation Program

PM360

They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,

article thumbnail

What a string of semaglutide biosimilars could mean for Mainland China

Clarivate

The company filed for marketing approval of their semaglutide biosimilar for the treatment of T2D with the National Medical Products Administration (NMPA) in April 2024, and this is expected to amplify clinical development of semaglutide biosimilars from domestic manufacturers in the next two to three years.